Biocon Biologics and Viatris launch Abevmy in Canada

Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020

Increased prevalence of diabetes and product innovation to boost insulin pens market in India, says GlobalData

India has the second-largest number of adults with diabetes globally, after China

Jubilant Ingrevia augments its CDMO presence with Rs 270 crore contract

Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer

Ineos to build acetonitrile plant in Germany

The new unit will be built with INEOS’ latest process technology and aims to substantially improve the sustainability of our supply to our customers and reduce our environmental impact

AGC to invest $100 million for expanding synthetic pharmaceutical production in Spain

The new facility is scheduled to start operation in the first half of 2024

PHARMAP 2022 to discuss contemporary issues

The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies

Wipro GE Healthcare bolsters leadership bench in India & South Asia

This announcement comes after the formation of a new Intercontinental Region within GE Healthcare, led by Chaillot

Prestige BioPharma’s Tuznue receives EU-GMP certification

Prestige BioPharma’s facility receives EU-GMP certification

The facility will manufacture its Herceptin biosimilar, Tuznue

WHO grants prequalification of Actemra/RoActemra for critical COVID-19 patients

Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra